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Vitreoretinal conferences seldom make the papers. And why would they? 
Most involve a relatively staid delivery of the clinical evidence, perhaps a few 
quips and rebuttals here and there, but without the drama of white-hot 
controversy. That remains the case, but the introduction of ocriplasmin did 
warm things up, a little.  
  
The build-up to ocriplasmin’s launch as a treatment for symptomatic 
vitreomacular adhesion keenly focussed our attention – would it transform the 
treatment landscape and put vitreoretinal surgeons out of work? The short 
answer was, of course, no.  Initial enthusiasm for the latest vitreoretinal 
innovation soon evaporated, to be replaced by a degree of scepticism.1, 2 
Efficacy appeared variable and significant side effects occurred in some 
patients including several cases with outer retinal changes postulated to be 
related to the drug’s off-target action on laminins in the interphotoreceptor 
matrix. Whilst ocriplasmin remains in use, market penetration is far below 
initial projections.  
 
 
Yet an important benefit of ocriplasmin’s introduction may be a renewed 
interest in nonsurgical treatment of vitreomacular traction (VMT) and macular 
hole.   
 
Enter intravitreal injection of expansile gas as an alternative means of 
releasing VMT. Or, more accurately, re-enter intravitreal gas (the technique 
was first reported as a treatment for macular hole in 1995, by Chan et al).3 
 On page XXX Claus and colleagues report their retrospective series of 20 
eyes receiving intravitreal gas injection for the treatment for VMT. ref Most 
patients received 0.2 mls of hexafluoroethane (C2F6) via a 30-gauge needle, 
combined with anterior chamber paracentesis. They instructed the majority of 
their patients to spend at least some time with their face down, moving their 
eyes left to right and back, to agitate the gas bubble and promote VMT 
release (although their data, and the findings of others, do not necessarily 
support the need for ocular calisthenics).  
They report a top-line result of 85% VMT release within 3 months. At 1 month 
they found 55% VMT release, which compares favorably with the 26.5% 
vitreomacular adhesion release at the 28-day primary endpoint of the pivotal 
ocriplasmin trials.4   
Their results are consistent with several other investigators using gas for the 
treatment of VMT or macular hole. Across a range of previous studies, 39 of 
83 eyes (47.0%) had anatomic success, defined as no VMT or macular hole 
and without recourse to PPV.3, 5-11 Taken together, these studies suggest, but 
don’t prove, that gas may be effective.  
If gas was proven safe and effective it has protean advantages. Gas is low 
tech, widely available and the infrastructure to deliver intravitreal injections is 
already in place. Unlike vitrectomy it does not require vitreoretinal surgeons to 
deliver treatment, and it is already licensed for intraocular injection (albeit not 
necessarily for the pneumatic release of VMT). Gas has a favorable safety 
profile when used as a treatment of other vitreoretinal disease. Storage is 
easy, preparation simple and there is potentially less variability in action 
related to its physical rather than proteolytic action.12 
But before we reignite our enthusiasm and plan to pack away our vitrectors 
(again), it is reasonable pause for thought. First up, the evidence comes from 
uncontrolled studies, and given that VMT may release spontaneously, a 
control group is important to estimate the magnitude of any therapeutic 
benefit. Secondly, rare safety events may not yet be evident in the small case 
series available, and with limited follow up, long terms safety is unknown.  
Claus and others report the progression of VMT to macular hole following gas 
injection.10,ref However, development of a macular hole does not necessarily 
preclude the use of gas, indeed, cases of VMT / stage 1 macular hole are 
often aptly described as an ‘impending’ macular hole, and hence development 
of a macular hole may not always be attributable to gas. There was also an 
appreciable (5.2%) rate of macular hole development in the pivotal 
ocriplasmin trials.4  
Gas could also cause raised intraocular pressure, central retinal artery 
occlusion, cataract, retinal breaks, retinal detachment, et al. Claus and 
associated noted that some patients had reduced vision and attributed this to 
the development of cataract, but they did not offer data in support of this 
hypothesis so it might best be regarded as speculative, indeed, it raises the 
possibility that VMT release can inherently damage vision. Perhaps at least 
some of the cases of presumed ocriplasmin toxicity reflect structural changes 
that occur alongside release of VMT?  These theoretical safety concerns and 
uncertainties can in part be mitigated by our experience with pneumatic 
retinopexy, which shows acceptable safety, but we should not automatically 
assume that those safety data can be transposed to a different disease.   
In conclusion, Claus et al should be congratulated for adding to the body of 
evidence in support of intravitreal gas for VMT. If gas is as good as it seems 
we have a very, very cheap treatment with few barriers to adoption; but how 
about some RCTs first?      
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